A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants

Vaccine

Volumn 25, Issue 51, 2007, Pages 8487-8499

  Nolan, Terry ^a   Lambert, Stephen ^a   Roberton, Don ^b   Marshall, Helen ^b   Richmond, Peter ^c   Streeton, Catherine ^d   Poolman, Jan ^e   Boutriau, Dominique ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d GLAXOSMITHKLINE   (Australia)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Neisseria meningitidis serogroup C; Neisseria meningitidis serogroup Y; Vaccine

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; CONJUGATE VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HEPATITIS B INACTIVATED POLIOVIRUS CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS C Y TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PEDIARIX; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CONJUGATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; ECZEMA; GASTROENTERITIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PEDIATRICS; PRIORITY JOURNAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP Y; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 36749067823     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.013     Document Type: Article

References (34)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180 6 (1999) 1894-1901
2. Pollard A.J., and Scheifele D. Meningococcal disease and vaccination in North America. Annu Rev Med 55 (2004) 333-353
3. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hugues J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
4. Lingappa J.R., et al., Active Bacterial Core surveillance (ABCs) team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 19 31 (2001) 4566-4575
5. Kaplan S.L., Schutze G.E., Leake J.A.D., Barson W.J., Halasa N.B., Byington C.L., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118 (2006) 979-984
6. Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 (2004) S274-S279
7. Keyserling H.L., Pollard A.J., DeTora L.M., and Gilmet G.P. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines 5 4 (2006) 445-459
8. Pediarix™ Summary of Product Characteristics.
9. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4 2 (1997) 156-167
10. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 32 (1994) 1475-1482
11. World Health Organization. Guidelines for WHO/EPI Collaborative Studies on Poliomyelitis-Standard Procedure for Determining Immunity to Poliovirus using the Microneutralization Test 1993:1-26 (http://www.who.int: WHO/EPI/GEN 1993.09, (1139):1-26).
12. Concepcion N., and Frasch C. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8 (2001) 266-272
13. Quataert S.A., Kirch C.S., Wiedl L.J., Phipps D.C., Strohmeyer S., Cimino C.O., et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 2 (1995) 590-597
14. Andrews N., Borrow R., and Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol 10 5 (2003) 780-786
15. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69 (2001) 1568-1573
16. Amato Neto V., Finger H., Gotschilch E.C., Feldman R.A., de Avila C.A., Konichi S.R., et al. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children. Rev Inst Med Trop Sao Paulo 16 3 (1974) 149-153
17. Henckaerts I., Goldblatt D., Ashton L., and Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 13 (2006) 356-360
18. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., and Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354 December (9195) (1999) 2063-2068
19. Käyhty H., Peltola, Karanko V., and Mäkelä P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147 (1983) 1100
20. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149 (1984) 1034-1037
21. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b disease among infants and children-United States, 1987-1995. MMWR Morb Mortal Wkly Rep. 1996;45(42):901-6.
22. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 February (7385) (2003) 365-366
23. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 October (Suppl. 1) (2001) S58-S67
24. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 9431 (2004) 365-367
25. Steinhoff M., and Goldblatt D. Conjugate Hib vaccines. Lancet 361 9355 (2003) 360-361
26. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 May (5) (1998) 2093-2098
27. Lagos R., Valenzuela M.T., Levine O.S., Losonsky G.A., Erazo A., Wasserman S.S., et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 351 (1998) 1472-1476
28. Gatchalian S, Pama CL, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. IJID, in press.
29. Schmitt H.J., Maechler G., Habermehl P., Knuf M., Saenger R., Begg N., et al. Immunogenicity, reactogenicity and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immun 14 (2007) 426-434
30. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus-toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun 69 April (4) (2001) 2378-2382
31. Pediacel™ Summary of Product Characteristics.
32. Kitchin N., Southern J., Morris R., Hemme F., Thomas S., Watson M., et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 92 1 (2007) 11-16
33. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine co-administered with a vaccine containing acellular pertussis components. Infect Immun 72 September (9) (2004) 5383-5391
34. Habermehl P., Leroux-Roels G., Säenger R., Maechler G., and Boutriau D. Immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C and Y-tetanus-toxoid conjugate (Hib-MenCY-TT) vaccine administered at 2, 3 and 4 months and as a booster dose at second year of life. 15th International Pathogenic Neisseria Conference (IPNC). Cairns, Australia, September 10-15 (2006) [abstract]